{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"1.00","pValueComment":"Two-sided significance level = 0.05","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.8","upperLimit":"86.8","value":"72.7"},{"groupId":"OG001","lowerLimit":"57.9","upperLimit":"87.8","value":"75.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"Fludeoxyglucose F-18 positron emission tomography/computed tomography (FDG-PET/CT) scans at baseline and four months after the end of radiation therapy are compared.\n\nPer RECIST 1.1:\n\n* Complete response:\n\n  * Disappearance of all lesions and pathologic lymph nodes\n* Partial response:\n\n  * ≥ 30% decrease sum of the longest diameters\n  * No new lesions\n  * No progression of non-target lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT+ Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Durvalumab"}],"paramType":"NUMBER","populationDescription":"Randomized participants with 4-month response assessed by PET","reportingStatus":"POSTED","timeFrame":"Baseline and 4 months after end of RT (approximately 6.5 months)","title":"Percentage of Participants With Complete or Partial Response at 4-month Scan Determined by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}